Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

1 to 13 of 13

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Change From Baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts II and III Combined Score	Week 26	mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline MDS-UPDRS assessment, and had available data for analysis.	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the MDS-UPDRS Part II Score	Week 26	mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline MDS-UPDRS assessment, and had available data for analysis.	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Percentage of Responders With Much Improved or Very Much Improved on Participant Global Impression of Change (PGIC)	Week 26	mITT Population includes subjects who receive at least 1 dose of study drug and have both a baseline and at least 1 postbaseline PGIC assessment, and had available data for analysis.	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Change From Baseline in the MDS-UPDRS Parts II and III Combined Score	Week 5, 8, 11, 14, 18, 22, 26, and 27	mITT Population	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the MDS-UPDRS Parts I, II and III Combined Score	Week 5, 8, 11, 14, 18, 22, 26, and 27	mITT Population	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the MDS-UPDRS Parts I, II and III Individual Score	Week 5, 8, 11, 14, 18, 22, 26, and 27	mITT Population	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the Clinical Global Impression - Severity of Illness (CGI-S) Score	Week 5, 8, 11, 14, 18, 22, 26, and 27	mITT Population	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Clinical Global Impression - Improvement (CGI-I) Score	Week 5, 8, 11, 14, 18, 22, 26, and 27	mITT Population	units on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the PGIC Score	Week 5, 8, 11, 14, 18, 22, 26, and 27	mITT Population	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the Epworth Sleepiness Scale (ESS)	Week 26	FAS population includes all randomized participants who received at least 1 dose of study drug, and had available data for analysis.	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Change From Baseline in the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS)	Week 26	FAS population includes all randomized participants who received at least 1 dose of study drug, and had available data for analysis.	score on a scale	LEAST_SQUARES_MEAN
SECONDARY	Columbia-Suicide Severity Rating Scale (C-SSRS)	Week 27	FAS population	Participants	COUNT_OF_PARTICIPANTS
SECONDARY	Number of Participants With Treatment Emergent Adverse Events (TEAEs)	From first dose of study drug until 190 days following last dose of study drug.	FAS Population	Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.govtrials-2026-11-12-0.4.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNone stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT04223193/outcomes

API reference For AI assistants